RxDoctor Payments DataLook up a doctor →

Molly Schooley, PA

Medical · Dakota Dunes, SDNPI 1225332463

Payments from drug & device makers

$104,809in general payments, 2019–2025

Across 527 payments — averaging $198.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$73K
  • Bayer$26K
  • Lilly USA, LLC$684
  • Novo Nordisk AS$595
  • Amgen$391
  • Pfizer$364
  • plus $3K from 43 others

What the payments were for

  • Consulting fees$15,75915%
  • Speaking & faculty fees$66,55464%
  • Travel & lodging$12,29412%
  • Food & beverage$10,15210%
  • Education$500%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$104,809 in reported general payments places this provider in the 95th percentile of 43 medical providers in South Dakota.

See all medical providers in South Dakota

Medicare billing

Part B allowed, 2024
$138,211
Medicare patients
278
Services billed
4,314

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide475$538,935
MounjaroTirzepatide269$294,474
JardianceEmpagliflozin380$287,229
Xultophy 100-3.6Insulin Degludec/Liraglutide201$277,204
FarxigaDapagliflozin Propanediol387$272,175
Tresiba Flextouch U-200Insulin Degludec260$271,592
TrulicityDulaglutide207$227,779
Tresiba Flextouch U-100Insulin Degludec321$140,008
Fiasp FlextouchInsulin Aspart (Niacinamide)135$103,335
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog70$99,667
Soliqua 100-33Insulin Glargine/Lixisenatide73$76,804
Humulin R U-500 KwikpenInsulin Regular, Human38$76,649
RybelsusSemaglutide34$56,583
JanuviaSitagliptin Phosphate89$52,909
Novolog FlexpenInsulin Aspart219$50,981

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus, Fiasp, Novolog$72,907$891,375752 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog, Lyumjev, Insulin Lispro$684$530,036531 claims
Boehringer IngelheimJardiance$256$287,229380 claims
AstraZenecaFarxiga$149$272,175387 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$153$76,80473 claims
MerckJanuvia$233$52,90989 claims
BayerKerendia$26,380$40,61552 claims
AbbVieSynthroid$316$5,91168 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 43 medical providers in South Dakota.

Other medical in Dakota Dunes

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →